Tenax Therapeutics Rises on Positive Phase 3 Heart Drug Data

Shares of Tenax Therapeutics (TENX) rose 3.8% in pre-open trading after the company presented additional positive data from its Phase 3 LEVEL clinical trial for its drug candidate, TNX-103 (oral levosimendan). The detailed findings were unveiled during a Late-Breaking Clinical Science session at the European Society of Cardiology Congress 2026 in Munich on August 29.

Key Clinical Data

The presentation, delivered by Professor Sanjiv Shah of Northwestern University, provided deeper insights into the trial for pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF), a condition with no currently approved treatments. The new data carries significant implications for the drug's potential regulatory path.

Key findings highlighted at the conference include:

• A confirmed favorable treatment effect in patients who had a lower baseline exercise capacity.
• Evidence that the drug's benefit appeared to increase with greater disease severity.
• A notable reduction in NT-proBNP, a widely used biomarker indicating cardiac wall stress. The company noted the magnitude of this effect exceeded that seen in other Phase 3 trials for heart failure therapies.

Analyst Confidence and Financial Position

Ad

The positive clinical update follows a series of optimistic initiations from Wall Street analysts. According to the source, several firms have recently started coverage with Buy-equivalent ratings and price targets ranging from $35 to $40, signaling institutional confidence in the TNX-103 program.

Financially, Tenax appears to be on solid footing. The company holds approximately $118 million in cash, which is expected to provide a funding runway through the second quarter of 2028 and removes near-term balance sheet concerns for investors.

Market Reaction

The stock's pre-market gain occurred even as major U.S. indices, including the S&P 500 and NASDAQ, were trading fractionally lower, indicating the move was driven by company-specific news rather than a broader market tailwind. Shares of TENX had been consolidating near multi-month lows since the initial topline data was released on August 10.

The detailed data presented at the high-profile cardiology conference appears to be serving as a fresh catalyst, prompting a re-evaluation of the stock by investors who were awaiting more scientific context.